Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Atlanta Cent Gastroenterology

Neither a doctor nor a teaching hospital

Research payments

$112,386

36 payments

Through program year 2023, Atlanta Cent Gastroenterology is reported as receiving $112,386 in research payments, across 36 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $6,159 1
2022 Research $6,547 7
2021 Research $55,101 9
2020 Research $19,794 11
2019 Research $24,785 8

Breakdown

Who paid Research payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $76,785 17 payments
  2. Shire North American Group Inc $17,785 5 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $10,816 11 payments
  4. Ironwood Pharmaceuticals, Inc $7,000 3 payments
Studies the money was for Research payments · program years 2019–2023
  1. Phase Iib Multi-Center, Randomised, Partial-Blind Parallel Cohort Stud $76,785 17 payments
  2. C3718-301 $7,000 3 payments
  3. Efficacy and Safety of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Crohns Disease Carmen CD 307 $6,835 2 payments
  4. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $5,950 2 payments
  5. Efficacy and Safety Study of Shp647 As Induction Therapy in Participants With Moderate to Severe Crohn's Disease $5,000 1 payment
  6. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (Figaro UC 302) $2,516 1 payment
  7. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (Figaro UC 302) $2,300 3 payments
  8. Efficacy and Safety of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Crohn?S Disease (Carmen CD 307) $1,750 2 payments
  9. A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida) $1,750 2 payments
  10. Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $1,750 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record